mRNA-1189
/ Moderna
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
October 01, 2025
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
(clinicaltrials.gov)
- P1 | N=482 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2027 ➔ Oct 2026 | Trial primary completion date: Jun 2027 ➔ Oct 2026
Enrollment closed • Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease
May 15, 2025
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
(clinicaltrials.gov)
- P1/2 | N=867 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease
April 03, 2025
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
(clinicaltrials.gov)
- P1 | N=474 | Recruiting | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Recruiting | N=354 ➔ 474
Enrollment change • Enrollment open • Epstein-Barr Virus Infections • Infectious Disease
February 20, 2025
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults
(clinicaltrials.gov)
- P1 | N=354 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Feb 2026 ➔ Jun 2027 | Trial primary completion date: Feb 2026 ➔ Jun 2027
Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease
December 05, 2024
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
(clinicaltrials.gov)
- P1/2 | N=842 | Recruiting | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Recruiting | Phase classification: P1 ➔ P1/2 | N=422 ➔ 842 | Trial completion date: Jun 2025 ➔ Oct 2026 | Trial primary completion date: Jun 2025 ➔ Oct 2026
Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease
February 01, 2024
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults
(clinicaltrials.gov)
- P1 | N=354 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease
November 21, 2023
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults
(clinicaltrials.gov)
- P1 | N=422 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease
July 10, 2023
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults
(clinicaltrials.gov)
- P1 | N=422 | Recruiting | Sponsor: ModernaTX, Inc. | N=272 ➔ 422 | Trial completion date: Jun 2023 ➔ Jun 2025 | Trial primary completion date: Jun 2023 ➔ Jun 2025
Enrollment change • Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease
April 26, 2023
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults
(clinicaltrials.gov)
- P1 | N=500 | Recruiting | Sponsor: ModernaTX, Inc.
New P1 trial • Epstein-Barr Virus Infections • Infectious Disease
December 20, 2021
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults
(clinicaltrials.gov)
- P1; N=272; Recruiting; Sponsor: ModernaTX, Inc.
Clinical • New P1 trial • Epstein-Barr Virus Infections • Infectious Disease
1 to 10
Of
10
Go to page
1